Michelle’s Hot Peeps Beat CC

Over 150 runners braved the Texas heat in Taylor, TX, on Saturday, Aug. 10th, to support the second annual “Michelle’s Hot Peeps Beat CC” 5K and Fun Run race to support finding a cure for cholangiocarcinoma. The event was planned in memory of Michelle McDonald who last her battle with the disease, at the age of 47, only five months after being diagnosed. More than 30 local sponsors generously supported the event, with Team CBS Austin’s Chelsea Thompson participating and placing second in her age division.  The event was an incredible success because of family, friends and supporters!  Next year’s date has already been set for August 8, 2020. Below are links sent from CBS TV from Austin, TX regarding the race John McDonald initiated for his late wife, Michelle.  The race was Sat, Aug 10th in Taylor, TX.  The local CBS affiliate gave generous coverage pre/post event and a...

Cholangiocarcinoma Foundation Awards $365k in Research Fellowship Grants in Largest Funding Cycle to Date

Cholangiocarcinoma Foundation Awards $365k in Research Fellowship Grants in Largest Funding Cycle to Date Since 2015, the Foundation has awarded more than $1.9 million in funding for innovative, high-quality research. SALT LAKE CITY, UTAH, USA, August 6, 2019 — The Cholangiocarcinoma Foundation (CCF), a nonprofit organization funding novel research for bile duct cancer, has awarded the 5th cycle of its Research Fellowship Program. CCF is pleased to support 7 projects for a total of $365,000 in its largest funding cycle to date. Since 2015, the Foundation has awarded more than $1.9 million in funding for innovative, high-quality research. In accordance with the Foundation’s Research Philosophy, CCF supports promising projects that are less likely to get traditional funding. Open-access research that catalyzes collaboration and focuses on finding a cure is a core value of the program. “Through these studies, CCF’s Research Fellowship Program aims to gain insights and achieve significant milestones into the research...

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Study Name Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene ClinicalTrials.gov Identifier (if applicable) NCT03602079 Clinical Trial Category (check all that apply) Beyond First Line Therapy Targeted Therapy Study Center Institution Name The University of Texas MD Anderson Cancer Center City Houston State Texas Zip Code 77030 Country United States List additional Institutions (include address, phone number, and website) Florida Cancer Specialists & Research Institute Sarasota, Florida, United States, 34232 Beth Israel Deaconess Medical Center Cancer Center Boston, Massachusetts, United States, 02215 Karmanos Cancer Institute Detroit, Michigan, United States, 48201 Clinical Research Alliance, Inc. Lake Success, New York, United States, 11042 Stephenson Cancer Center Oklahoma City, Oklahoma, United States, 73104 Providence Cancer Institute Portland, Oregon, United States, 97213 Mary Crowley Cancer Research Centers – Medical City Dallas, Texas, United States, 75230 South Texas Accelerated Research Therapeutics, LLC (START) San Antonio, Texas,...

A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients with Locally Advanced, Recurrent, or Metastatic Biliary Tract Cancers

Study Name • A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients with Locally Advanced, Recurrent, or Metastatic Biliary Tract Cancers ClinicalTrials.gov Identifier (if applicable) • NCT03801083 Clinical Trial Category (check all that apply) Immunotherapy Other Novel Therapy Study Center Institution Name UPMC Hillman Cancer Center Institution Address • 5115 Centre Ave City Pittsburgh State Pennsylvania Zip Code 15232 Country United States Phone (412) 647-2811 Website https://hillman.upmc.com/find/locations/hillman-cancer-center-pittsburgh-pa List additional Institutions (include address, phone number, and website) https://hillmanresearch.upmc.edu/ https://hillman.upmc.com/research/ Study Contacts Principal Investigator Dr. Udai Kammula P.I. Phone (412) 692-2852 P.I. Email kammulaus@upmc.edu Study Coordinator Krystle Eaton Study Coordinator Phone (412) 623-7957 Study Coordinator Email mientkiewiczk@upmc.edu List additional Study Coordinators (include phone number and email) • Samantha Perkins PA-C 412-623-5960 OVERVIEW – in layman’s terms (150 words max) This Phase 2 study will be conducted in conjunction with the...

A Phase 3, First Line Study of Pemigatinib vs Gemcitabine/Cisplatin in Patients with Cholangiocarcinoma

Study Name A Phase 3, First Line Study of Pemigatinib vs Gemcitabine/Cisplatin in Patients with Cholangiocarcinoma ClinicalTrials.gov Identifier (if applicable) NCT03656536 Clinical Trial Category (check all that apply) First Line Therapy Study Center Institution Name Incyte Corporation Institution Address 1815 Augustine Cut Off City Wilmington State Delaware Zip Code 19803 Country United States Phone (855) 463-3463 Study Contacts Principal Investigator Tanios Bekaii-Saab, MD P.I. Phone (855) 463-9463 P.I. Email TBD@XYZ.com List additional Principal Investigators (include phone number and email) Please refer to the Clinical Trials. gov listing and contact the Incyte Help Line at 855-463-3463 for a site list Study Coordinator TBD Study Coordinator Phone (855) 463-3463 Study Coordinator Email TBD@XYZ.com List additional Study Coordinators (include phone number and email) Please refer to the Clinical Trials. gov listing and contact the Incyte Help Line at 855-463-3463 for a site list OVERVIEW – in layman’s terms (150 words max) This...

TELE-ABC

Study Name TELE-ABC ClinicalTrials.gov Identifier (if applicable) NCT03790111 Clinical Trial Category (check all that apply) First Line Therapy Other Novel Therapies Study Center Institution Name Lexicon Pharmaceuticals, Inc. Institution Address 8800 Technology Forest Place City The Woodlands State Texas Zip Code 77381 Country United States Phone (281) 863-3000 Website http://www.lexpharma.com Study Contacts Principal Investigator N/A P.I. Phone (000) 000-0000 P.I. Email NA@notapplicable.com Study Coordinator Karie Arnold Study Coordinator Phone (281) 863-3317 Study Coordinator Email karnold@lexpharma.com OVERVIEW – in layman’s terms (150 words max) There is a Screening Period of up to 42 days. This is followed by a Treatment Period with multiple cycles. Each cycle of the Treatment Period is 21 days. This period lasts until disease progression, signs of toxicity, or until the patient decides to stop the treatment. Next, there is a Follow-up Period that could last as long as 24 months. Enrollment 54 Study Start Date...

FUZE Clinical Trial

Study Name FUZE Clinical Trial ClinicalTrials.gov Identifier (if applicable) NCT03834220 Clinical Trial Category (check all that apply) Beyond First Line Therapy Targeted Therapy Study Center Institution Name Massachusetts General Hospital Institution Address 165 Cambridge Street, Suite 302 City Boston State Massachusetts Zip Code 02114 Country United States Phone (617) 724-4000 Website https://patients.debiopharm.com/genetic-alterations List additional Institutions (include address, phone number, and website) United States, Arizona University of Arizona Cancer Center 1515 N Campbell Avenue Tucson, AZ 85724 Phone: +1 (520) 626-7866 United States, California Moores University of California, San Diego Cancer Center 3855 Health Sciences Drive MC 0698 La Jolla, CA 92093 Phone: +1 (858) 246-1102 University of California, San Francisco 1600 Divisadero, Suite B-718 San Francisco, CA 94115 Phone: +1 (510) 579-5972 United States, Florida H. Lee Moffitt Cancer Center & Research Institute 1209 Magnolia Drive FOW-EDU Tampa, FL 33612 Phone: +1 (813) 745-2226 United States, Louisiana Tulane Cancer...

2019 Annual Conference Videos

All of the presentations at our 2019 Annual Conference are online and waiting to be viewed! Visit our Conference in Review page for photos, a recap video and videos from many of the presentations, or if you prefer, visit our YouTube Channel, where we have all of the Conference Videos arranged into a...

Changing Lives Fundraiser

EVENT INFORMATION: Friday, February 15, 2019 — 6:00 – 10:00 PM The Salem Waterfront Hotel — 225 Derby Street Salem, MA 01970 Food Open Cash Bar Silent Auction Fun & Dancing with DJ Nick! Theme: Wear Green! Prize awarded for best dressed! To purchase tickets, please contact Caitlin Fortuna at: https://changinglivesfund.wixsite.com/fundraiser Adults: $23 Children: $20 (Under 3 yrs: Free) Event proceeds after expenses will go to the Cholangiocarcinoma...

Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

Study Name Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy ClinicalTrials.gov Identifier (if applicable) NCT03639935 Clinical Trial Category (check all that apply) Beyond First Line Therapy Study Center Institution Name University of Michigan Institution Address 1500 E Medical Center Dr., Rogel Cancer Center City Ann Arbor State Michigan Zip Code 48109 Country United States Phone (734) 936-4991 List additional Institutions (include address, phone number, and website) Dana-Farber Cancer Institute Vanderbilt University Medical Center Study Contacts Principal Investigator Vaibhav Sahai, MD P.I. Phone (734) 936-4991 P.I. Email CTSU-Oncology-Multisite@med.umich.edu Study Coordinator Dominique Dippman, RN Study Coordinator Phone (734) 647-8902 Study Coordinator Email CTSU-Oncology-Multisite@med.umich.edu OVERVIEW – in layman’s terms (150 words max) The investigators are studying the benefit of daily oral targeted therapy (rucaparib) in conjunction with every 2 week infusional immunotherapy (nivolumab) in...

Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

Study Name Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors ClinicalTrials.gov Identifier (if applicable) NCT03678883 Clinical Trial Category (check all that apply) Beyond First Line Therapy Chemotherapy Targeted Therapy Other Novel Therapy Study Center Institution Name Rhode Island Hospital Institution Address rovidence, Rhode Island, United States, 02903 City Providence State Rhode Island Zip Code 02903 Country United States Phone (401) 444-3234 Website https://www.lifespan.org/centers-services/cancer-research-and-clinical-trials Study Contacts Principal Investigator Benedito Carneiro, MD P.I. Phone (401) 444-3234 P.I. Email Benedito.Carneiro@Lifespan.org Study Coordinator Jennifer Renaud Study Coordinator Phone (401) 444-3234 Study Coordinator Email JRenaud@Lifespan.org OVERVIEW – in layman’s terms (150 words max) A clinical trial of a new drug known as 9-ING-41, that will take place in patients with tumors or cancers that affect the blood and lymph system. 9-ING-41...

Tree Topp

Study Name Tree Topp ClinicalTrials.gov Identifier (if applicable) NCT03093870 Clinical Trial Category (check all that apply) Beyond First Line Therapy Chemotherapy Study Center Institution Name UT MD Anderson Cancer Center Institution Address University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd, Unit 426, FC10.2051 City Houston State TX Zip Code 77030 Phone 1-877-250-3770 Website mdanderson.org Study Contacts Principal Investigator Dr. Milind Javle P.I. Phone (713) 794-1623 P.I. Email mjavle@mdanderson.org Study Coordinator Kimberly Ross Study Coordinator Phone 713-794-1623 Study Coordinator Email kdross@mdanderson.org List additional Study Coordinators (include phone number and email) Charlotte, North Carolina – Levine Cancer Institute, Carolinas Healthcare System 1021 Morehead Medical Dr.  Charlotte, NC  28204; (980) 442-2000 Contact: Study Coordinator – Melani Terry, (980)-442-2157, Melani.Terry@atriumhealth.org Dallas, Texas – Texas Oncology, P.A., Texas Oncology Sammons Cancer Center 3410 Worth Street, Suite 730 , Dallas, TX 75246; www.texasoncology.com Contact: Study Coordinator -Catinna Mallett, (214)-370-1949 Detroit, Michigan – Karmanos Cancer...

GNS561-CL-I-Q-0211: Phase 1/2 Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients with Primary Liver Cancer which includes Intrahepatic cholangiocarcinoma patients

Study Name GNS561-CL-I-Q-0211: Phase 1/2 Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients with Primary Liver Cancer which includes Intrahepatic cholangiocarcinoma patients ClinicalTrials.gov Identifier (if applicable) NCT03316222 Clinical Trial Category (check all that apply) Beyond First Line Therapy Chemotherapy Other Novel Therapy Study Center Institution Name Memorial Sloan Kettering Institution Address 300 E 53rd St City New York State New York Zip Code 10065 Study Contacts Principal Investigator Pr James Harding P.I. Phone (646) 888-4314 P.I. Email hardinj1@mskcc.org List additional Principal Investigators (include phone number and email) Pr Ghassan Abou-Alfa, (646) 888-4184, abou-alg@mskcc.org Study Coordinator Amanda Simms Study Coordinator Phone (646) 888-4314 Study Coordinator Email simmsa@mskcc.org List additional Study Coordinators (include phone number and email) Brittanie Millans, millangb@mskcc.org OVERVIEW – in layman’s terms (150 words max) This is a multicenter, open-label, uncontrolled, repeat-dose phase 1/2a study designed to evaluate the safety profile and to determine...
Translate »

Pin It on Pinterest